Sigmoid Colon Cancer: Symptoms, Diagnosis, and Treatment

Sigmoid colon cancer is a malignancy that forms in the S-shaped final segment of the large intestine, just before the rectum. Because of its location in the lower left abdomen, it tends to produce noticeable symptoms earlier than cancers higher up in the colon, yet those symptoms overlap heavily with common benign conditions like diverticulitis and hemorrhoids. That overlap means people frequently dismiss early warning signs for months. Understanding what to watch for, how the disease is found and staged, and what treatment looks like in practice can make a meaningful difference in outcomes.

Where the Sigmoid Colon Sits and Why It Matters

The sigmoid colon is roughly 35 to 40 centimeters of bowel that connects the descending colon to the rectum. Its name comes from the Greek letter sigma, reflecting its curved shape. The segment is tethered to the back wall of the abdomen by a fan of tissue called the sigmoid mesocolon, whose exact shape and attachment point vary across individuals and populations.¹ The sigmoid’s relatively narrow diameter compared to the right colon means that tumors growing here can obstruct the bowel at smaller sizes, which is one reason left-sided colon cancers more often lead to emergency surgery than right-sided ones.

Left-sided colon cancers, including sigmoid tumors, tend to behave somewhat differently from right-sided colon cancers in their biology, presentation, and prognosis. Large population studies consistently show that left-sided cancers carry a modest survival advantage. One analysis of more than 100,000 patients found median survival of 89 months for left-sided colon cancers compared with 78 months for right-sided ones.² A Belgian population study confirmed that pattern, reporting five-year relative survival around 68% for left-sided colon cancer versus about 66% for right-sided disease.³

Symptoms and Early Warning Signs

Because the sigmoid colon has a narrower channel and sits close to the rectum, tumors here tend to cause symptoms that are hard to ignore once they reach a certain size. The most common include visible blood in the stool (often bright red rather than the dark, tarry blood associated with right-sided tumors), a persistent change in bowel habits such as new-onset constipation or alternating constipation and diarrhea, crampy left-sided abdominal pain, and a feeling of incomplete emptying after a bowel movement. Unintentional weight loss and fatigue can develop as the disease progresses.

The tricky part is that every one of these symptoms also shows up in far more common conditions. Hemorrhoids cause rectal bleeding. Irritable bowel syndrome causes alternating bowel habits. Diverticulitis, which occurs in the same segment of bowel, causes left-lower-quadrant pain. Data from clinical series show that left-sided colon cancers lead to emergency (urgent) surgery more often than right-sided ones, reflecting the risk of acute obstruction or perforation when a sigmoid tumor blocks the narrower lumen.⁴ Any rectal bleeding, new change in bowel habits, or persistent abdominal pain lasting more than a few weeks warrants medical evaluation, particularly if you are over 40 or have a family history of colorectal cancer.

Screening and How the Cancer Is Found

Many sigmoid colon cancers are detected through routine screening before symptoms ever appear. Colonoscopy remains the gold standard: it visualizes the entire colon, allows removal of precancerous polyps during the same procedure, and has been linked to a roughly 74% reduction in colorectal cancer mortality in observational studies, compared with about 35% for flexible sigmoidoscopy.⁵ The additional benefit of colonoscopy over sigmoidoscopy translates to roughly 12 fewer cancer cases per 100,000 person-years.⁶

When a suspicious mass is found, biopsy during colonoscopy confirms whether it is cancerous. From there, imaging is used to determine how far the cancer has spread. CT scans with contrast are the workhorse for preoperative staging, providing accurate assessment of local tumor extent and distant metastases.⁷ CT colonography, sometimes called virtual colonoscopy, can also detect polyps and masses when a traditional colonoscopy is incomplete or not feasible. MRI plays a supporting role, particularly for evaluating whether the tumor invades adjacent structures or for assessing liver metastases.⁸

The Diverticulitis Problem

One of the most common diagnostic headaches in sigmoid colon cancer is distinguishing it from diverticulitis. Both conditions strike the same part of the bowel, both affect a similar age group, and on imaging they can look disturbingly alike. CT scans can help: features that favor diverticulitis include extensive inflammation around the colon wall and a long segment of involvement (more than 10 cm), while features pointing toward cancer include enlarged nearby lymph nodes and a visible mass in the lumen.⁹ Even so, an unequivocal CT diagnosis is only reached in a minority of cases.¹⁰

This is why guidelines generally recommend a follow-up colonoscopy after an episode of diverticulitis, particularly in patients over 50 or those with risk factors for colorectal cancer. A cancer hiding behind what looked like a straightforward bout of diverticulitis is not rare enough to ignore.

Molecular Profiling and What It Changes

Once sigmoid colon cancer is confirmed, the tumor’s molecular profile increasingly drives treatment decisions. Pathologists now routinely test for mutations in the KRAS, NRAS, and BRAF genes, as well as microsatellite instability (MSI) status. In one representative cohort, KRAS mutations were found in about 40% of colorectal cancer patients, NRAS mutations in roughly 7%, and BRAF V600E mutations in under 5%.¹¹

These markers matter because they shape which drugs will and won’t work. Tumors with RAS mutations (KRAS or NRAS) do not respond to anti-EGFR antibodies like cetuximab and panitumumab, so testing spares patients from an ineffective and expensive therapy. BRAF V600E mutations carry a worse prognosis, shortening survival by roughly 10 to 16 months in metastatic disease, and also predict poor response to anti-EGFR drugs.¹² Tumors with high microsatellite instability respond well to immunotherapy drugs called checkpoint inhibitors, making MSI testing particularly consequential for treatment planning.

Surgery for Sigmoid Colon Cancer

Surgery is the primary treatment for non-metastatic sigmoid colon cancer. The standard operation is a sigmoid colectomy (also called anterior resection), which removes the affected segment along with its blood supply and surrounding lymph nodes, then reconnects the remaining bowel. Current guidelines call for examining at least 12 lymph nodes to ensure accurate staging.

Most sigmoid resections today are performed laparoscopically or robotically. A propensity-matched comparison of robotic versus laparoscopic approaches for stage II and III sigmoid cancer found that robotic surgery achieved less blood loss and harvested more lymph nodes, though it took longer and cost more. Three-year overall survival was similar between the two approaches, around 91 to 93%.¹³ A randomized trial comparing extended versus standard complete mesocolon excision found no difference in lymph node yield, complications, or survival between the two approaches, suggesting that a well-performed standard operation is sufficient.¹⁴

When the Cancer Causes an Obstruction

If the sigmoid tumor has blocked the bowel entirely, surgeons face a tougher decision. The traditional approach is emergency surgery, which often results in a temporary or permanent stoma (a bag on the abdomen for stool collection). An alternative is placing a self-expanding metal stent through the blockage as a bridge to scheduled surgery a few weeks later. Studies show that the stent-then-surgery approach dramatically reduces the stoma rate (under 10% versus nearly half with emergency surgery), allows far more procedures to be done laparoscopically, and cuts the rate of major postoperative complications roughly in half, without compromising long-term survival.¹⁵

Chemotherapy and Targeted Therapy

After surgery, whether you need additional (adjuvant) chemotherapy depends primarily on the cancer’s stage. Stage I disease almost never requires chemotherapy. Stage III disease (cancer in regional lymph nodes) is routinely treated with chemotherapy, typically a fluoropyrimidine-based regimen with or without oxaliplatin for three to six months. Stage II disease falls in a gray area where the decision depends on individual risk features like tumor perforation, poorly differentiated histology, or too few lymph nodes examined.

For metastatic sigmoid colon cancer, systemic treatment combines chemotherapy with targeted agents. Left-sided tumors, including sigmoid cancers, respond better to anti-EGFR antibodies than right-sided tumors do, though registry data from metastatic colorectal cancer patients found no significant difference in overall survival between anti-EGFR antibodies and bevacizumab (an anti-VEGF drug) as first-line additions to chemotherapy for either left- or right-sided tumors.¹⁶ The choice among targeted agents is increasingly guided by the molecular testing described above rather than tumor location alone.

Bowel Function After Surgery

One aspect of sigmoid cancer treatment that patients rarely hear enough about is how their bowel works afterward. Removing part of the sigmoid colon disrupts the coordinated wave-like contractions that push stool toward the rectum. A large survey-based study of more than 3,000 patients who had sigmoid resections found that 12 common bowel symptoms were significantly more prevalent compared with patients who had polyps removed without resection. About 17% of patients in the resection group reported that bowel symptoms substantially impaired their quality of life, versus 10% in the polypectomy group. Symptoms of obstructed defecation were especially common, affecting about 18% of the resection group.¹⁷

Constipation stands out as a particular problem after sigmoid resection. One study found that patients who had their sigmoid colon removed were roughly three times more likely to develop constipation than patients who had a right hemicolectomy.¹⁸ While major low anterior resection syndrome (the severe bowel dysfunction more commonly associated with rectal cancer surgery) is less frequent after sigmoid resection than after very low rectal surgery, it still affects roughly one in five sigmoid cancer patients.¹⁹ Patients who have a temporary stoma that is later reversed may experience an additional period of bowel adjustment, with some facing persistent difficulties that affect physical, social, and psychological wellbeing.²⁰

The practical upshot: ask your surgical team specifically about expected bowel changes before the operation, and if problems develop afterward, bring them up rather than assuming they are something you just have to live with. Dietary adjustments, pelvic floor physiotherapy, and medications can help.

Surveillance After Treatment

After curative surgery (with or without chemotherapy), you enter a surveillance period designed to catch any recurrence early. The standard program includes periodic physical exams, blood tests for carcinoembryonic antigen (CEA), CT scans, and colonoscopy. CEA is the most commonly used blood marker, though its accuracy for detecting recurrence is limited.²¹ Stage III disease and rising CEA levels after surgery are the strongest independent predictors that cancer will come back.²²

How intensive should surveillance be? A large French randomized trial (PRODIGE-13) tested whether adding CT scans or CEA monitoring to standard follow-up improved survival. After five years, there was no significant difference in overall survival across groups receiving intensive imaging, standard imaging, CEA monitoring, or no CEA monitoring. Five-year overall survival hovered between roughly 80% and 84% regardless of the surveillance strategy used.²³ This finding has prompted ongoing debate about how much surveillance imaging is truly necessary and whether less intensive protocols might spare patients the anxiety and radiation exposure of frequent scans without sacrificing outcomes.

Risk Factors and the Rise in Younger Patients

The major modifiable risk factors for sigmoid colon cancer are the same as for colorectal cancer generally. Eating red and processed meat increases risk, with evidence from ecological, case-control, and cohort studies consistently pointing in the same direction for both men and women.²⁴ A healthy lifestyle overall, encompassing diet, physical activity, body weight, alcohol use, and smoking avoidance, is inversely associated with colon cancer risk. A composite healthy-lifestyle score was linked to roughly a 21% lower risk per standard-deviation improvement.²⁵

One of the most alarming trends in colorectal cancer epidemiology is its rising incidence in people under 50. Since the early 1990s, the incidence in younger adults has nearly doubled, and about one in 10 new colorectal cancer diagnoses now occurs in someone 50 or younger.²⁶ This early-onset disease disproportionately involves the distal colon and rectum, making the sigmoid colon a frequent site.²⁷ The causes behind this shift remain under active investigation, but the pattern is why screening guidelines in many countries now recommend starting at age 45 rather than 50.

The Microbiome Connection

Research into the gut bacteria associated with colorectal cancer has identified one organism in particular, a mouth-dwelling bacterium called Fusobacterium nucleatum, as a key player. This bacterium is enriched in colorectal tumor tissue at levels about four times higher than in adjacent normal tissue.²⁸ It is not merely a bystander: studies show it promotes the malignant behavior of colorectal cancer cells through multiple mechanisms, including suppressing anti-tumor immune responses and stimulating inflammatory signaling.²⁹

Analysis of a Norwegian cohort confirmed that Fusobacterium-specific genes are actively expressed across multiple colonic sites, including the sigmoid colon and tumor tissue, and that their abundance correlates with pro-inflammatory immune gene expression in the local tissue environment.³⁰ From a practical standpoint, Fusobacterium enrichment is being investigated as a potential prognostic biomarker. In patients with metastatic colon cancer, those whose right-sided tumors were enriched with this bacterium had shorter progression-free survival than other subgroups.²⁸ Whether targeting this organism therapeutically could improve outcomes remains an open question, but the connection between oral bacteria, gut inflammation, and colorectal cancer is one of the more intriguing areas of current research.